A Chinese pharmaceutical company and Aerogen have teamed up to create an inhalation Covid-19 vaccination.
According to CanSinoBio, the inhaled vaccine uses a lesser dose, making vaccination of a greater number of individuals around the world more affordable.
CanSinoBio is using Aerogen’s aerosol drug delivery technology to offer a more efficient way of delivering its Convidecia vaccine. The businesses have partnered on supply and commercial development.
Convidecia Air, an inhaled vaccination, received emergency use approval as a booster dosage in China earlier this year. Shanghai was the first city to start adult booster vaccinations via inhalation in October.
Using a cup dispenser, the aerosolised vaccination is administered directly into the patient’s airway. This resembles the Covid-19 infection process in nature.
The businesses claimed that a far lower dose of the vaccine may be used to effectively administer the inhaled form of Convidecia. The CanSinoBio vaccine can now be affordably accessed by more patients than would have been possible with an injectable method.
The inhaled vaccine is currently undergoing clinical testing in Asia and Latin America, according to the two businesses. According to CanSinoBio, Morocco last week approved the use of its vaccine for emergency situations. Aerogen specialises in acute care aerosol medicine delivery, and more than 16 million patients have been treated in 75 different countries using its technology. It received the Irish Medtech Awards’ Medtech Company of the Year honour in 2020.